Program
ripretinib
Also written as “Ripretinib” and “DCC-2618”.
Its studies are mostly in Gastrointestinal Stromal Tumors, led by 2 companies.
Drug pageRipretinib: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ono Pharmaceuticalits history only | 73 open or running | phase 3since Nov 20, 2017 | Oct 5, 2015 | Dec 2027phase 3 · NCT05734105 |
| Zai Lab | 20 open or running | phase 2since Feb 21, 2020 | Feb 21, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Zai Lab only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2018Named ripretinibINNProposed as its International Nonproprietary Name in WHO's List 119 · before, DCC-2618
- Feb 21, 2020First study: phase 2 study in Gastrointestinal Stromal TumorsFirst studyNCT04282980 · 39 enrolled · China
- Nov 11, 2020Phase 2 study in Gastrointestinal Stromal TumorsNCT04633122 · 108 enrolled · China
TargetBeta
“An orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), ”NCIt, by rule
“Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 40 |
| Avapritinibrule | Sanofi | phase 4 | 10 |
| masitinibrule | AB Science | phase 3 | 38 |
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
Studies
All 2 Zai Lab leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04633122Gastrointestinal Stromal Tumors · China | 2 | Completed | Jul 20, 2022 | 108 |
| NCT04282980Gastrointestinal Stromal Tumors · China | 2 | Completed | Feb 26, 2021 | 39 |
How it is read
Names in the registry
- “Ripretinib”, 5 entries
- “DCC-2618”, 5 entries
Conditions, from the studies’ own filings
- Gastrointestinal Stromal Tumors, 9 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.